SGSergiu Groppa

Sergiu Groppa

*This is an algorithmically generated author record based on publicly available information.

Sergiu Groppa has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Digital Twins in Clinical Neurology: From Concept to Clinical Application in Multiple Sclerosis

    by Isabel Voigt, Hernan Inojosa, Judith Wenk, Iva Gasparovic‐Curtini, Sergiu Groppa, Matthias Grothe, Marc Pawlitzki, Lars Masanneck, Sven Meuth, Stephen Gilbert, et al.

    Introduction: Patient digital twins (DT) are emerging as a promising paradigm for personalised and predictive healthcare. In neurology, and particularly in multiple sclerosis (MS), the availability of longitudinal, multimodal data provides a strong foundation for developing patient‐specific digital models, including simulation‐based and mechanistic approaches. However, it remains unclear to what extent current approaches represent integrated, clinically embedded DT systems. Methods: We conducted a narrative review to synthesise current concepts, modelling approaches and translational challenges of DT in neurology, using MS as an illustrative use case. Existing approaches were mapped to core DT components, including data integration, predictive modelling, dynamic updating and clinical integration. Results: Current DT‐related approaches in MS demonstrate substantial progress across complementary development tracks, including multimodal data integration, predictive modelling, digital biomarkers, mechanistic simulations, virtual‐patient frameworks and in silico trials. These capabilities represent important building blocks of DT development but have not yet been fully integrated into continuously operating clinical systems. Core DT functionalities, including continuous bidirectional data exchange, real‐time model updating and closed‐loop interaction with clinical workflows, remain limited. Key challenges include data fragmentation, limited interoperability, lack of standardised validation, and regulatory, ethical and economic constraints. Conclusion: MS represents a highly suitable model domain for DT development. Future progress will depend on further maturing and validating individual modelling and data‐integration capabilities, as well as on their integration into continuously updating, clinically embedded systems. Robust validation, scalable infrastructures and appropriate governance frameworks will be essential to establish safe, effective and clinically actionable use in practice.

  • Open Access

    Multifocal continuous theta burst stimulation in idiopathic generalized epilepsy: a cohort study

    by Pavel Leahu, Anatolie Vataman, Dumitru Ciolac, Vitalie Chiosa, Stanislav Groppa, Gabriel Gonzalez-Escamilla, Sergiu Groppa, Yaroslav Winter

  • Open Access

    Cerebellar Transcranial Alternating Current Stimulation: Frequency-Specific Modulation of Human Gait

    by Marc Varel, Michael Doppelmayr, Sergiu Groppa, Traian Popa, Manuel Bange, Adrian Zeitner

    Coordinated locomotion depends on rhythmic neural interactions, with the cerebellum contributing to movement timing and scaling. However, how cerebellar oscillatory dynamics influence human gait remains unclear, despite its relevance for motor learning and rehabilitation. We hypothesized two frequency-dependent effects: (i) gait-matched cerebellar transcranial alternating current stimulation (c-tACS) would produce stronger phase alignment than sham and selectively affect temporal rather than spatial gait parameters; and (ii) higher-frequency stimulation would preferentially modulate spatial gait parameters without consistent phase alignment with the ongoing locomotor rhythm. To test this, fifteen healthy adults received randomized bilateral c-tACS at their individual gait-cycle frequency (iGCF), iGCF ± 10% offsets, individual step frequency (iSF), a harmonic in alpha range (iGCF×10), 50 Hz (gamma), and sham. Head-mounted accelerometry recorded kinematics of continuous walking and a stop-and-go task. Phase synchrony between stimulation and gait periodicity was quantified using the debiased phase-locking value (dPLV). 50 Hz c-tACS increased gait velocity and stride length without altering cadence or stride time, indicating selective modulation of spatial gait parameters. In contrast, gait-matched stimulation (iGCF, iSF) produced strong stimulation-gait phase alignment but did not enhance temporal gait parameters beyond sham, arguing against entrainment-specific behavioral effects. dPLV declined with iGCF ± 10% during continuous walking, whereas a transient increase at iGCF-10% during stop-and-go was not specific to active stimulation. These findings support frequency-dependent effects of c-tACS on locomotion and refine the mechanistic understanding of how rhythmic cerebellar stimulation interacts with gait control, with potential implications for targeted neuromodulation.

  • Open Access

    Trends in mortality and disability from ischaemic stroke in Europe, 1990-2023

    by Francesco Brigo, Andrea Zini, Sergiu Groppa, Yaroslav Winter, Piergiorgio Lochner

    Introduction: The burden of ischaemic stroke in Europe has evolved over recent decades, shaped by changes in prevention, acute care and population ageing. Understanding long-term trends in mortality and disability is essential for guiding policy and service planning. Patients and methods: Using Global Burden of Disease (GBD) 2023 estimates, we analysed age-standardised disability-adjusted life years (DALYs), years of life lost (YLLs) and years lived with disability (YLDs) for ischaemic stroke across all European countries from 1990 to 2023. We estimated country-specific annual percentage changes (EAPCs), assessed non-linear trajectories, examined shifts in the fatal vs non-fatal composition of DALYs and synthesised trends using mixed-effects models and descriptive meta-analytic pooling. Results: Disability-adjusted life year rates declined in every European country, with the steepest reductions in Central and Western Europe and more modest improvements in parts of Eastern and Southeastern Europe. Years of life lost declines closely paralleled DALY trends, indicating that falling premature mortality was the main driver of the overall reduction. Years lived with disability trends were smaller and more heterogeneous across countries. Mixed-effects modelling indicated average European EAPCs of −3.40% (95% CI, −3.74 to −3.05) for DALYs, −1.26% (−1.43 to −1.09) for YLLs and −3.86% (−4.26 to −3.46) for YLDs. Meta-analytic pooling of national patterns showed large declines in YLLs (random-effects EAPC −3.81%) relative to YLDs (−0.86%). Discussion and conclusion: Ischaemic stroke burden has fallen substantially across Europe, driven primarily by reductions in premature mortality. Slower progress in disability outcomes and persistent regional disparities highlight the need to strengthen long-term rehabilitation and address uneven improvements across the continent.


  • Open Access

    Abnormal motor control effort costs in Parkinson's disease patients with apathy

    by Johannes Schönhals, Moaz Al Ajia, David Meder, Gabriel Gonzalez-Escamilla, Nils Schröter, Sergiu Groppa, Damian M Herz

    Background: In Parkinson's disease, abnormalities in reward-effort trade-offs are thought to underlie both apathy and bradykinesia. However, it remains unclear whether effort cost computations contribute to these symptoms independently of reward, and which exact effort costs are involved. Objective: To assess whether effort-based decision-making in the absence of any explicit rewards differs between Parkinson patients and healthy controls and to explore whether putative differences are related to apathy or bradykinesia. Methods: To address this, we developed a novel decision-making task that isolated physical effort costs from reward processing. Twenty-one Parkinson patients tested on and off dopaminergic medication, and 20 healthy participants, had to choose between two options that differed only in their requirements of force effort, either requiring larger total amounts of force or greater changes in force. We quantified participants’ preference for these different effort types and their sensitivity to changes in relative effort. Results: Patients differed from healthy participants in both overall effort preference ( P = 0.009) and sensitivity to changing efforts ( P = 0.036), being more likely to choose options requiring overall lower force levels and more influenced by increasing requirements of changes in force. These effects were unaffected by dopaminergic medication. Importantly, sensitivity to increasing requirements for changes in force was associated with apathy ( P = 0.004), but not bradykinesia. Conclusion: Our findings suggest that, beyond well-known diminished responses to potential rewards, apathy in Parkinson's disease is related to aberrant effort cost computations, in particular those involving dynamic changes in movement, during decision-making.


  • Open Access

    Disease modification in advanced Parkinson’s disease: a review and roadmap for paving the way for next-generation interventions

    by Sergiu Groppa, Alfonso Fasano, Daniele Urso, Xinjie Yang, Bogdan Popescu, Peter Klivenyi, Teus van Laar, Wolfgang Jost, Pedro J. Garcia-Ruiz, Roongroj Bhidayasiri, et al.

    Parkinson’s disease (PD) exhibits highly heterogeneous clinical trajectories, yet “advanced PD” (aPD) lacks a standardized definition. Current reliance on clinical milestones (e.g., motor fluctuations, cognitive decline) is limited by non-linear progression and the absence of objective measures. Although biomarkers like aggregated α-synuclein, MRI, and PET are under investigation, their correlation with clinical progression remains modest. Robust, reproducible endpoints are urgently needed to evaluate disease-modifying therapies across diverse phenotypes, accounting for genetic background, age of onset, co-pathologies, and motor/autonomic/cognitive domains. Given this complexity, single-target interventions are likely insufficient. We propose a multi-domain therapeutic framework for aPD that integrates: (A) simultaneous targeting of key pathological cascades, including α-synuclein aggregation, mitochondrial dysfunction, oxidative stress, proteostasis imbalance, neuroinflammation, and the gut–brain axis; (B) biology-driven patient stratification using emerging biomarkers to match subgroups with targeted interventions; and (C) systematic management of comorbidities and lifestyle factors, such as cardiovascular health and exercise, to enhance neuroresilience. Finally, advancing aPD care requires addressing systemic determinants, including global healthcare inequities, and prioritizing caregiver well-being. Mechanistically informed, patient-centered strategies that combine multi-target therapies with precision stratification and holistic support will be essential to modify disease progression and improve long-term outcomes.


  • Open Access

    Oligodendrocyte subtype diversity underlines clinical progression in Parkinson’s disease

    by Daniela Mirzac, Nils Schroeter, Yann Decker, Martin B. Glaser, Matthias Huelser, Svenja L. Kreis, Heiko J. Luhmann, Viviane Almeida, Jenny Blech, Sebastian Kunz, et al.

    Despite growing evidence for glial involvement in Parkinson’s disease, oligodendrocyte dysfunction remains poorly defined. To address this gap, we compared single-cell RNA sequencing from a mouse model of α-synuclein aggregation pathology with fresh human brain tissue from deep brain stimulation surgery to build a cross-species framework of disease progression. In total, we profiled over 200,000 cortical transcriptomes, including 55,000 oligodendrocytes. Early disease in mice was characterized by inflammatory activation, while advanced stages in both species converged on metabolic dysfunction, including impaired ribosomal output, chaperone stress responses, ubiquitination deficits, and lysosomal perturbation. In patients, APLP1 was upregulated and correlated with clinical disease progression and increased levodopa demand, linking α-synuclein spread in oligodendrocytes to disease severity. APP and CNTN pathways emerged as key signalling axes, with CNTN reflecting weakened reparative communication and reduced resilience. Together, these findings define oligodendrocyte subtype dynamics as shared and clinically relevant features of PD progression.

  • Open Access

    Protocol of the interdisciplinary and intersectoral randomized controlled trial in Parkinson patients in a specialized network in Germany: the INSPIRE Trial

    by Susanne A. Schneider, Sandra Paryjas, Franziska Beyer, Jan-Philipp Bach, Simon Baudrexel, Bernhard Baier, Moaz Al Ajia, Ilona Csoti, Klaus Gehring, Gabriel Gonzalez Escamilla, et al.

    INSPIRE-PNRM+ (short for InterdiSciPlinary and InteRsectoral telemedIcal Evaluation, Coordination and Therapy at the ParkinsonNet RheinMain+) is an one-year, multicentre, interventional, open-label, two-arm, 1:1 randomized controlled trial (RCT) with the goal to improve the quality of care for Parkinson’s disease (PD) patients outside of a specialized clinical context. The study is funded by the German Innovation Fund mandated by the Federal Joint Committee (G-BA). The three core characteristics are (1) the employment of specially trained advanced practice nurses (APN) in an (2) interdisciplinary network and (3) the use of a specifically designed digital platform. This platform serves for documentation and communication, thereby helping patients receive individualized, guideline-based treatment and support in adapting their lives to the effects of the disease. 844 patients will be recruited. They will be divided into two groups: a “usual care” group which continues traditional care (i.e., usually consultation with a neurologist in private practice) vs. the “intervention” group which will have APN contact every three months or more frequently as needed over the period of 12 months. Patients’ quality of life serves as primary outcome measure, combined with a process evaluation and health economic analysis (cost-utility analysis (CUA)). Recruitment was ongoing at time of submission of this paper. This innovative study is the first in Germany where APNs are dedicated to PD care. The study may serve as blueprint when incorporating APNs into routine healthcare, similar to other countries. Trial registration: The study has been registered at www.clinicaltrials.gov , NCT06479083. Registered June 27, 2024. https://clinicaltrials.gov/study/NCT06479083?term=INSPIRE%20Parkinson&rank=1 .


  • Open Access

    Cognitive trajectories in Parkinson’s disease patients, a review on the impact of subthalamic deep brain stimulation (STN-DBS) and emerging adaptive strategies

    by Viviane Almeida, Damian M. Herz, Jenny Blech, Matthias Hülser, Joachim Oertel, Daniel Martens, Gabriel González-Escamilla, Sergiu Groppa

    While deep brain stimulation (DBS) is well-established for managing motor symptoms in Parkinson’s disease (PD) and improving patient’s quality of life, its impact on cognition is still not properly addressed. Cognitive impairment in PD often affects verbal fluency, attention, and executive functions, and may interact with disease progression, dopaminergic medication, and stimulation parameters. These outcomes are shaped not only by the stimulation itself but also by factors such as baseline cognitive status, lead location, disease heterogeneity, and parameter selection. The emerging development of closed-loop DBS (CL-DBS) offers a promising tailored neuromodulation strategy that may help reduce DBS side effects while enhancing non-motor function. Given the extensive yet heterogeneous literature on cognitive outcomes after STN-DBS, this review integrates mechanistic insights from human and animal studies to clarify how stimulation parameters, anatomical targeting, and network-level dynamics influence postoperative cognitive trajectories. We summarize established cognitive effects of conventional DBS, emphasize sources of interindividual variability, and evaluate how adaptive stimulation paradigms may modulate cognitive and decision-making processes. Finally, we outline translational considerations for biomarker development and personalized neuromodulation strategies aimed at preserving cognition while maintaining motor benefit.


  • Open Access

    Macroscale Gradient‐Informed Neural Oscillation Topography in Parkinson's Disease

    by Hao Ding, Ke Xie, Manuel Bange, Hannah Kühne, Jenny Blech, Bahman Nasseroleslami, Jens Volkmann, Sergiu Groppa, Muthuraman Muthuraman

    Background: Parkinson's disease (PD) is characterized by large‐scale disruptions in beta and gamma oscillations. Although subcortical beta power is an established biomarker for current adaptive deep brain stimulation (aDBS), it may not fully capture the global pathophysiological burden and the macroscale hierarchical reorganization of the cortex. Objective: We characterize the frequency‐specific reorganization of the cortical hierarchy across resting and motor states using functional gradients. We sought to identify topographic biomarkers that emerge across different behavioral states and determine whether these hierarchical features provide predictive power for global motor severity. Methods: High‐density electroencephalography and magnetic resonance imaging–based source reconstruction were employed in patients with PD (n = 35) and healthy control subjects (n = 34). To characterize cortical connectivity transitions, we applied a manifold learning framework to derive frequency‐specific functional gradients. We quantified the diagnostic and predictive utility of these hierarchical features and performed transcriptomic enrichment analysis to validate the biological relevance of the alterations. Results: Patients with PD exhibited a macroscale reorganization of the cortical hierarchy that was both frequency specific and state dependent. These gradient‐based biomarkers effectively differentiated patient groups and significantly predicted global Unified Parkinson's Disease Rating Scale Part III severity. Findings showed a robust framework with distinct topographical signatures, manifesting as a redistribution of informative signals across cortical regions. Conclusions: This work demonstrates that PD induces a macroscale reorganization of the cortical hierarchy. State‐dependent topographical biomarkers effectively predict clinical severity and align with the disease pathological landscape. By identifying optimal sensing sites across distributed networks, our findings provide a principled reference to support next‐generation, cortical‐guided aDBS. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.